Mara Koelker

Mara Koelker

Auto-generated profile, based on publicly available information

Mara Koelker

Division of Urological Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, MA; Center for Surgery and Public Health, Harvard Medical School, Brigham and Women's Hospital, Boston, MA; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2023 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
NFNicola Frego
Nicola Frego
EBEdoardo Beatrici
Edoardo Beatrici
MLMuhieddine Labban
Muhieddine Labban
BSBenjamin V. Stone
Benjamin V. Stone
DFDejan K. Filipas
Dejan K. Filipas
ACAlexander P. Cole
Alexander P. Cole

28 September 2022 in BJU International
Verified
Journal Article
Open access
MDMarkus von Deimling
Markus von Deimling
Michael RinkMichael Rink
Michael Rink
JKJakob Klemm
Jakob Klemm
MKMara Koelker
Mara Koelker
FKFrederik König
Frederik König
MVMalte W. Vetterlein
Malte W. Vetterlein
Objectives: To validate the pentafecta criteria (PC) proposed by the PROMETRICS group for outcome reporting after radical cystectomy in an open radical cystectomy (ORC) cohort with long‐term follow‐up and to assess the discriminative ability of PC attainment for oncological endpoints. Patients and Methods: Between January 2009 and December 2017, 420 patients underwent ORC with pelvic lymph node dissection and urinary diversion for non‐metastatic bladder cancer. The PC were defined as reported by the PROMETRICS group. The primary endpoint was PC attainment, and oncological outcomes comprised further endpoints. We used uni‐ and multivariable logistic regression analysis to assess predictors of PC attainment. The discriminative ability of PC for overall mortality (OM), cancer‐specific mortality (CSM) and other‐cause mortality (OCM) was compared using Kaplan–Meier curves and cumulative incidence functions. After stratification by the number of PC attained, the association between PC attainment and the survival endpoints was tested on multivariable Cox regression and competing‐risks models. Results: A total of 108 patients (26%) fulfilled all PC, while 195 (46%), 77 (18%), 35 (8.3%) and five (1.2%) attained 4/5, 3/5, 2/5 and ≤1/5 PC, respectively. Increasing age‐adjusted Charlson comorbidity index (odds ratio [OR] 0.80, P = 0.015) and incontinent diversion (OR 0.38, P = 0.005) were independent predictors of PC non‐attainment. The median follow‐up was 73 months. PC attainment (≥4/5 vs 3/5 vs ≤2/5 PC attained) was used to stratify patients into groups at significantly different risk of death ( P < 0.001). A decreasing number of PC attained (<4/5) was associated with unfavourable survival estimates for both OM and CSM (all P ≤ 0.005) but not for OCM (all P ≥ 0.2). Conclusions: The PC proposed by the PROMETRICS group represent accurate quality indicators for oncological outcome reporting after ORC for non‐metastatic bladder cancer and have a distinct discriminative ability to predict long‐term OM and CSM.

31 July 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
ZQZhiyu Qian
Zhiyu Qian
DFDejan K. Filipas
Dejan K. Filipas
MKMara Koelker
Mara Koelker
BSBenjamin V. Stone
Benjamin V. Stone
EBEdoardo Beatrici
Edoardo Beatrici
ACAlexander P. Cole
Alexander P. Cole

14 September 2023 in The Prostate
Verified
Journal Article
Closed access
MKMara Koelker
Mara Koelker
MLMuhieddine Labban
Muhieddine Labban
NFNicola Frego
Nicola Frego
JYJamie Ye
Jamie Ye
SLStuart R. Lipsitz
Stuart R. Lipsitz
MLMuhieddine Labban
Muhieddine Labban

22 July 2022 in Research Square
Verified
Preprint
Open access
PDF file
ACAlexander Cole
Alexander Cole
MKMara Koelker
Mara Koelker
MLMuhieddine Labban
Muhieddine Labban
NFNicola Frego
Nicola Frego
CMChristian P. Meyer
Christian P. Meyer
QTQuoc-Dien Trinh
Quoc-Dien Trinh
BACKGROUND: Local ablative therapies, a partial-gland treatment for localized prostate cancer (PCa), offers targeted cancer treatment while minimizing side-effects. We aim to describe national-level patterns in its use for localized PCa in the United States (U.S.).METHODS:We retrospectively interrogated the hospital-based National Cancer Database (NCDB) for men with clinically localized PCa from 2010-2017. The main outcome was receipt of local tumor ablation with either cryo or laser-ablation, and other focal therapy including high-intensity focused ultrasound (HIFU). Patient level, hospital level, and demographic variables were collected. A mixed effects logistic regression analysis was utilized to identify covariates and predictors on the patient- and hospital-level. RESULTS: Overall, 11 278 patients received ablative therapy. Cryotherapy was performed in 8 883 (78.8%), laser ablation in 1 755 (15.6%), and other focal therapy (HIFU) in 640 (5.7%) cases. On the patient-level, intermediate-risk PCa patients were more likely to be treated with ablative therapy (OR 1.05, 95% CI 1.00 – 1.11, p=0.05) than low-risk PCa patients, as were men with Charlson Comorbidity Index >1 (OR 1.36, 95%CI 1.29 -1.43, p<0.01), men between 71-80 years (OR 3.70, 95%CI 3.43-3.99, p<0.01), men with Medicare insurance (OR 1.38, 95% 1.31-1.46, p<0.01), and an income <$47 999 (OR 1.16, 95% 1.06-1.21, p<0.01). On the hospital-level, local ablative therapy was less likely to be performed in academic/research facilities (OR 0.45, 95% CI 0.32-0.64, p<0.01), while hospitals with a high annual caseload were more likely to perform local ablative therapies (2nd quartile, OR 1.23, 95% CI 1.12-1.35, p<0.01). CONCLUSIONS: In this study, we report trends from 2010-2017, in utilization of local ablative therapies using a large national database of U.S. cancer centers. The technique is more commonly used in older men with comorbidities. The financial aspects of ablative therapy need to be addressed to avoid inequity in access to care.